Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Adar1 Partners, a ten percent owner of Keros Therapeutics, Inc. (NASDAQ:KROS), has sold 5,390,264 shares of common stock at a price of $17.75 on October 15, 2025. The total value of the shares sold amounts to $95,659,436. The sale price represents a premium to the current trading price of $14.75, with the stock having declined 75% over the past year. According to InvestingPro analysis, the company maintains a "GREAT" financial health score despite the price decline.
The sales were executed by ADAR1 Partners, LP (4,391,237 shares), ADAR1 SPVI, LP (254,669 shares) and Spearhead Insurance Solutions IDF, LLC (743,358 shares).
Daniel Schneeberger, as Manager, signed on behalf of ADAR1 Capital Management, LLC, ADAR1 Partners, LP, and ADAR1 Capital Management GP, LLC.
In other recent news, Keros Therapeutics, Inc. has announced agreements to repurchase shares from ADAR1 Capital Management and Pontifax Venture Capital for a total of approximately $181 million. This transaction is part of Keros’ $375 million capital return program and will be funded from existing cash reserves. Additionally, Keros reported positive clinical data for its Duchenne muscular dystrophy (DMD) drug candidate, KER-065, from a Phase 1 trial, presented at a recent medical conference. The U.S. Food and Drug Administration has also granted Orphan Drug designation to KER-065 for the treatment of DMD, supporting its advancement into Phase 2 clinical trials. Meanwhile, H.C. Wainwright has lowered its price target for Keros to $20, maintaining a Buy rating, following the company’s strategic focus on KER-065. This decision comes after Keros discontinued cibotercept due to safety concerns and outlicensed elritercept to Takeda. In a separate development, ADAR1 Capital Management expressed dissatisfaction with Keros’ board for declining to engage in strategy discussions, despite being the company’s largest shareholder.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.